α-Methyl-α-phenylsuccinimide ameliorates neurodegeneration in a C. elegans model of TDP-43 proteinopathy
Open Access
- 1 October 2018
- journal article
- research article
- Published by Elsevier in Neurobiology of Disease
- Vol. 118, 40-54
Abstract
No abstract availableKeywords
Funding Information
- Wellcome Trust (102378/Z/13)
- U.S. Department of Veterans Affairs (I01BX003755, I01BX002619)
- University of Liverpool
- MRC Clinical Research Capabilities and Technologies Initiative (MR/M009114/1)
This publication has 62 references indexed in Scilit:
- FDA-Approved Drugs that Protect Mammalian Neurons from Glucose Toxicity Slow Aging Dependent on Cbp and Protect Against ProteotoxicityPLOS ONE, 2011
- Amyloid-binding compounds maintain protein homeostasis during ageing and extend lifespanNature, 2011
- Phosphorylation Promotes Neurotoxicity in aCaenorhabditis elegansModel of TDP-43 ProteinopathyThe Journal of Neuroscience, 2010
- Fluoxetine protects against amyloid-beta toxicity, in part via daf-16 mediated cell signaling pathway, in Caenorhabditis elegansNeuropharmacology, 2010
- Moving beyond Rules: The Development of a Central Nervous System Multiparameter Optimization (CNS MPO) Approach To Enable Alignment of Druglike PropertiesACS Chemical Neuroscience, 2010
- Does neuroinflammation fan the flame in neurodegenerative diseases?Molecular Neurodegeneration, 2009
- Identifying the proteins to which small-molecule probes and drugs bind in cellsProceedings of the National Academy of Sciences, 2009
- The Anticonvulsant Ethosuximide Disrupts Sensory Function to Extend C. elegans LifespanPLOS Genetics, 2008
- TDP‐43 A315T mutation in familial motor neuron diseaseAnnals of Neurology, 2008
- Identification of Potential Therapeutic Drugs for Huntington's Disease using Caenorhabditis elegansPLOS ONE, 2007